| Literature DB >> 30274868 |
Tomonori Hayashi1, Heather E Lynch2, Susan Geyer3, Kengo Yoshida4, Keiko Furudoi4, Keiko Sasaki4, Yukari Morishita4, Hiroko Nagamura4, Mayumi Maki4, Yiqun Hu4, Ikue Hayashi5, Seishi Kyoizumi4, Yoichiro Kusunoki4, Waka Ohishi6, Saeko Fujiwara7, Munechika Misumi8, Ivo Shterev9, Janko Nikolich-Žugich10, Donna Murasko11, Laura P Hale12, Gregory D Sempowski13, Kei Nakachi4.
Abstract
The objective of this study was to evaluate effects of whole body radiation exposure early in life on influenza vaccination immune responses much later in life. A total of 292 volunteers recruited from the cohort members of ongoing Adult Health Study (AHS) of Japanese atomic bomb (A-bomb) survivors completed this observational study spanning two influenza seasons (2011-2012 and 2012-2013). Peripheral blood samples were collected prior to and three weeks after vaccination. Serum hemagglutination inhibition (HAI) antibody titers were measured as well as concentrations of 25 cytokines and chemokines in culture supernatant from peripheral blood mononuclear cells, with and without in vitro stimulation with influenza vaccine. We found that influenza vaccination modestly enhanced serum HAI titers in this unique cohort of elderly subjects, with seroprotection ranging from 18 to 48% for specific antigen/season combinations. Twelve percent of subjects were seroprotected against all three vaccine antigens post-vaccination. Males were generally more likely to be seroprotected for one or more antigens post-vaccination, with no differences in vaccine responses based on age at vaccination or radiation exposure in early life. These results show that early life exposure to ionizing radiation does not prevent responses of elderly A-bomb survivors to seasonal influenza vaccine.Entities:
Keywords: Antibodies; Atomic-bomb radiation; Chemokine; Cytokine; Influenza vaccine; Radiation
Mesh:
Substances:
Year: 2018 PMID: 30274868 PMCID: PMC8172087 DOI: 10.1016/j.vaccine.2018.09.054
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641